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Muscle wasting is one of the main features of cancer cachexia, a multifactorial syndrome frequently occurring in oncologic patients.
The onset of cachexia is associated with reduced tolerance and response to antineoplastic treatments, eventually leading to clinical
conditions that are not compatible with survival. Among the mechanisms underlying cachexia, protein and energy dysmetabolism
play a major role. In this regard, several potential treatments have been proposed, mainly on the basis of promising results obtained
in preclinical models. However, at present, no treatment yet reached validation to be used in the clinical practice, although several
drugs are currently tested in clinical trials for their ability to improve muscle metabolism in cancer patients. Along this line, the
results obtained in both experimental and clinical studies clearly show that cachexia can be effectively approached by a
multidirectional strategy targeting nutrition, inflammation, catabolism, and inactivity at the same time. In the present study,
approaches aimed to modulate muscle metabolism in cachexia will be reviewed.
1. Introduction
Cancer-induced muscle wasting is one of the hallmarks of
cachexia, a multifactorial syndrome that represents one of
the most important comorbidities in oncologic patients.
The occurrence of cachexia markedly complicates the man-
agement of cancer patients, negatively impinging on the tol-
erance and response to antineoplastic treatments, worsening
the quality of life, and reducing survival. In particular, about
25% of deaths by cancer are due to cachexia, rather than to
the tumor itself [1].
Few years ago, a classification of cachexia was proposed,
defining three different stages: precachexia, cachexia, and
refractory cachexia [2]. Prognosis progressively worsens
going from patients with precachexia to those with
refractory cachexia. In this regard, the earlier anticachexia
treatments are set up, the better. For this reason, the research
on cachexia is focused on two main goals: (i) to find out
biomarkers useful to the early identification of a condition
of still latent cachexia and (ii) to define treatment
protocols useful to delay the progression from precachexia
to refractory cachexia.
Skeletal muscle wasting in cancer patients has a good
prognostic value, being predictor of reduced tolerance to che-
motherapy and/or surgery, decreased ability to perform daily
activities, and shortened survival. In addition, recent data
report that loss of muscle mass negatively affects quality of
life in cancer patients [3, 4]; such correlation might occur
irrespectively of survival rates [5]. Being poor quality of life
one of the most prominent and invalidating consequences
of cancer cachexia, to investigate the mechanisms underlying
cancer-induced muscle wasting is even more relevant to
design therapeutic strategies that also take into account
patient well-being.
The possibility to underestimate the occurrence of mus-
cle mass depletion exists, since the first approach to clinically
evaluate a patient is to obtain information about body weight
and body mass index (BMI). However, in face of no body
weight loss and/or normal BMI, reduced muscle mass might
well occur, being masked by fat or water content. Another
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relevant point that frequently is poorly taken into consider-
ation is that the loss of muscle mass is likely exacerbated by
anticancer treatments.
At present, different mechanisms have been proposed to
lead to muscle wasting in cancer hosts, among which there
are altered protein and energy metabolism and impaired
myogenesis [1]. Several factors may contribute to these alter-
ations, such as reduced calorie intake, hormonal unbalance,
and systemic inflammation.
Cancer-driven production of proinflammatory cytokines
plays a relevant role in tumor progression and markedly
contributes to cachexia. Indeed, in cancer patients, systemic
inflammation correlates with increased resting energy expen-
diture and with reduced survival rate [6]. Along the same
line, increased circulating levels of tumor necrosis factor α
(TNFα), interleukin-6 (IL-6), γ-interferon (INF), and, more
recently, growth and differentiation factor 15 (GDF15) have
been reported in cachectic cancer patients [1, 7]. The link
existing between cytokines and cachexia has led to the inclu-
sion of anti-inflammatory drugs in treatment protocols [8].
The present review will focus on strategies able to modu-
late metabolism that may reveal useful to prevent/delay
cancer-induced muscle wasting.
2. Protein and Amino Acid Metabolism
Altered protein turnover is a general feature of muscle wast-
ing in cancer cachexia. In particular, protein breakdown rates
are persistently increased, while protein synthesis rates can
be reduced, unchanged, or even increased, depending on
the model system [1]. The different reaction kinetics that
characterizes protein synthesis and degradation rates, zero
and first order, respectively, implies that if degradation is
higher than normal, the loss of total protein cannot be
antagonized by simply increasing the rate of synthesis.
Taking this assumption for true, any anabolic approach
should be associated with anticatabolic strategies in order
to achieve a beneficial effect on muscle protein mass.
2.1. Protein Degradation. Several pieces of evidence suggest
that the intracellular proteolytic systems in the skeletal
muscle of cancer hosts are poised towards activation above
the physiological levels (Figure 1). Particularly relevant in
this regard are the pathways dependent on ubiquitin-
proteasome and autophagy. While the former mainly
degrades short-lived and regulatory proteins, the latter gets
rid of structural proteins and organelles [9].
Both experimental and human cancer cachexia were
associated with increased activity of the ubiquitin-
proteasome pathway [1]. Of interest, alterations in molecular
and biochemical markers of proteasome activation were
observed in gastric cancer patients before any evidence of
body weight loss, supporting the need to detect cachexia as
early as possible [10]. Modulations of the ubiquitin-
proteasome proteolytic system, however, are not a general
finding in cancer cachexia, as shown by studies reporting that
it is not differently activated with respect to controls in the
muscle of patients affected by non-small-cell lung cancer
(NSCLC; [11]) or esophageal cancer [12].
The involvement of the autophagic-lysosomal proteolysis
in muscle wasting was recognized just in the last fifteen years.
Two main reasons account for such delay: (i) autophagy was
not considered as typically operated by the skeletal muscle as
a response to stress conditions. Such belief was definitely
abandoned when autophagy was clearly demonstrated in
fasted mice overexpressing green fluorescent protein-
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Figure 1: Main catabolic pathways contributing to protein breakdown in cancer cachexia.
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labeled LC3 [13]. (ii) The study and detection of autophagy
was not easy since the ATG genes were not discovered [14].
A number of studies reported that the autophagic system
was overactivated, without reaching complete cargo degra-
dation, in the muscle of both tumor-bearing animals and
cancer patients [6, 15–17]. In particular, despite autophagic
flux was enhanced in mice bearing the C26 tumor, autopha-
gosomes accumulated, likely due to exhaustion of the lyso-
somal compartment [15]. A similar pattern could also be
observed in cancer patients, as suggested by LC3B-II and
p62 accumulation [16, 17].
Both proteasome and lysosomes, however, cannot
directly degrade intact myofilaments. In this regard, a
preliminary cleavage was proposed to be operated by other
proteolytic systems, such as those dependent on caspases or
calpains. These latter are Ca2+-dependent cysteine proteases,
normally inactive and localized in the cytosolic compart-
ment. When intracellular Ca2+ concentrations increase, inac-
tive calpains translocate to the cell membrane and become
activated by autoproteolysis [18]. The system also includes
calpastatin, a physiological inhibitor, which is a substrate of
active calpain itself. Increased calpain expression was
reported in the muscle of tumor-bearing animals [19], while
rats transplanted with the Yoshida AH-130 hepatoma
showed a progressive reduction of calpastatin levels and
increased in vitro cleavage of specific fluorogenic substrates
[20]. More recently, calpain activation was also demonstrated
in mice bearing the C26 colon carcinoma [21]. Both
increased or unchanged muscle calpain expression were
reported in cancer patients [12, 22].
Several lines of evidence show that proinflammatory
cytokines act as triggers, or at least as contributors, of
cancer-induced protein hypercatabolism [23]. Briefly, data
obtained in both experimental models and human pathology
have demonstrated that cytokines such as TNFα and IL-6
lead to reduced rates of protein synthesis paralleled by
enhanced protein breakdown, both accounting for the loss
of muscle mass [24]. Such effects depend, at least in part,
on activation of the transcription factor NF-κB, as shown
in both experimental and human cancer cachexia patients
[25, 26]. Cancer-induced muscle wasting has also been
associated with another proinflammatory cytokine, namely,
TNF-like weak inducer of apoptosis (TWEAK) [27].
The therapeutic approaches mainly pursued by
researchers to counteract enhanced muscle protein break-
down have long been those specifically targeting the differ-
ent proteolytic systems. The results, however, did not
really clarify the issue.
Since the discovery of muscle-specific ubiquitin ligases,
these were considered a good target to interfere with protein
breakdown, being involved in determining both substrate-
specificity and proteasome degradation rate. Among the
enzymes belonging to this family, the first described were
MAFbx/atrogin-1 and MuRF1/TRIM63, respectively,
involved in the degradation of structural proteins and of
proteins contributing to cell proliferation, differentiation,
and survival [1]. Subsequently, other members came out,
such as TRIM32 and FBXO40. More recently, FBXO30/
MUSA1 was shown to contribute to denervation- and
fasting-mediated muscle loss [28], as well as to cancer-
induced muscle wasting (unpublished data). Genetic
approaches specifically targeting these ubiquitin ligases
proved effective in protecting the muscle against protein
depletion [29]; however, at present, the use of these enzymes
as therapeutic targets for muscle wasting is not validated yet.
On the other side, the inhibition of proteasome activity
by means of pharmacological inhibitors was effective just in
few models of muscle atrophy but totally unable to protect
tumor-bearing animals against muscle wasting [30]. In con-
trast with these findings, few years ago, a study reported that
inhibition of the ubiquitin-proteasome pathway by MG132
was able to improve experimental cancer cachexia [31].
However, MG132 is a rather unspecific inhibitor, being able
to block also calpains and autophagy [31, 32]. Finally, carfil-
zomib, an irreversible selective inhibitor of proteasome
chymotrypsin-like activity, was shown to improve cachexia
in tumor-bearing mice by inhibiting muscle protein break-
down [31]. Such improvement, however, was associated with
reduced tumor burden, which could be the real mechanism
underlying the beneficial effect of the treatment.
Several lines of evidence proposed that modulations of
autophagy could be useful to improve cancer-associated
muscle wasting. In this regard, muscle-specific gene strategies
aimed at silencing Beclin-1, one of the proteins involved in
autophagosome formation, showed that suppression of
autophagy in the C26 hosts was unable to rescue myofiber
diameter (unpublished data). In addition, pharmacological
inhibition of autophagy in mice hosting the C26 tumor lead
to death of the animals, suggesting that lysosomal degrada-
tion is mandatory to sustain the requirement of both energy
and substrates in tumor hosts, at least when they are facing
the terminal phase of cancer growth [15]. The other way
round, excessive stimulation of muscle autophagy, experi-
mentally obtained by the overexpression of TP53INP2/
DOR, exacerbated muscle atrophy in tumor-bearing mice
(unpublished data), while activation of autophagy by means
of the mTOR inhibitor rapamycin was shown to positively
affect the skeletal muscle in the C26 hosts [16]. Such discrep-
ancy might depend on the fact that while mTOR inhibition
affects stress-induced autophagy, TP53INP2 hyperexpres-
sion targets basal autophagy.
Despite the literature report data supporting the involve-
ment of Ca2+-dependent proteolysis in the pathogenesis of
cancer-induced muscle wasting, protein hypercatabolism
was not downregulated in preparations of isolated muscles
obtained from tumor-bearing animals and incubated in
the presence of calpain inhibitors [19, 33, 34]. More
recently, both pharmacological and genetic approaches
aimed at inhibiting the Ca2+-dependent proteolytic system
were not able to prevent or delay cancer-induced muscle
wasting [21], although contrasting results were reported
in this regard [35].
While interfering with specific proteolytic systems does
not seem to be an appropriate approach to prevent/delay
cancer-induced muscle wasting, the modulation of bulk
protein turnover appears more promising. In this regard,
anti-inflammatory approaches revealed able to improve
muscle protein turnover in tumor-bearing mice [20]. More
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recently, administration of formoterol, a β2-adrenergic
agonist, to tumor-bearing animals revealed able to reverse
muscle wasting [36]. Such an effect is mainly exerted by stim-
ulating protein synthesis and inhibiting protein degradation
rates. In particular, both the ubiquitin-proteasome and the
autophagic-lysosomal proteolytic systems were downregu-
lated in formoterol-receiving animals ([24]; unpublished
data). At present, only one study evaluated the effectiveness
of formoterol, combined with megestrol acetate, in cachectic
cancer patients [37]. The results suggest that both muscle size
and strength can be improved by the treatment, although
more trials are needed to draw clear-cut evidence.
2.2. Protein Synthesis. As reported above, depending on the
situation, reduced, normal, or even increased muscle protein
synthesis rates were shown in cancer cachexia. Due to the
rapid development of cachexia, tumor-bearing animals fre-
quently show reduced protein synthesis rates, although this
is not a general finding. Indeed, rats bearing the AH-130 hep-
atoma, that usually die about 10 days after tumor transplan-
tation, showed muscle protein synthesis rates comparable to
those of healthy animals [38]. The situation is more complex
when studying human pathology. Reduced muscle protein
synthesis was reported many years ago in patients affected
by different types of tumors [39] and more recently in pros-
tate cancer patients [40]. On the contrary, van Dijk et al.
[41] reported that baseline protein synthesis rates were
higher than control values in cachectic patients affected
by pancreatic cancer. Also, intermediate results are avail-
able in the literature: myofibrillar protein synthesis rates
were analyzed in healthy people and weight-stable and
weight-losing gastrointestinal cancer patients and found
comparable among the different groups. Similarly, no
changes in whole body protein synthesis were reported
in NSCLC patients [42].
The possibility to modulate protein synthesis in order to
correct muscle atrophy or simply to provide an environment
permissive for the maintenance of muscle mass was long
studied. Many approaches were tested, most of them consist-
ing in nutritional strategies or in molecular modulations
aimed at pushing muscle metabolism towards anabolism.
Most of these approaches revealed unsuccessful, giving rise
to the idea that anabolic resistance occurs in cancer cachexia.
Just to provide few examples, conventional nutritional
supplementation or the infusion with an amino acid cocktail
did not stimulate muscle protein synthesis in advanced can-
cer patients [42]. Along this line, studies aimed at stimulating
the anabolic pathway depending on IGF-1, by both pharma-
cological and genetic means, did not succeed in improving
muscle wasting in tumor-bearing animals [43, 44].
Recently, however, patients not yet considered as
refractory cachectic were proposed to display an anabolic
window that could be exploited with nutritional interven-
tions [42, 45, 46] or with other anabolism-inducing strate-
gies. As an example, patients with stage III and IV NSCLC
showed a normal anabolic response to hyperaminoacidemia
but not to isoaminoacidemia, suggesting that high substrate
availability is relevant to induce anabolism in cancer hosts
[47]. Consistently, muscle protein synthesis could be
stimulated in advanced cancer patients by a high protein for-
mula versus a conventional nutritional supplement [48, 49].
These observations point out the possibility to overcome
the anabolic resistance that occurs in cancer patients by pro-
viding specifically enriched nutritional supplements.
Stimulation of anabolism can be exerted by several
means. Particularly interesting in this regard is ghrelin, a
mediator released by the stomach during fasting or caloric
restriction. Modulations of ghrelin levels exert remarkable
effects on both energy and protein metabolism, such as the
inhibition of autophagy in conditions characterized by sys-
temic inflammation [50]. The administration of ghrelin to
tumor-bearing animals improved food intake, body weight,
lean body mass, and chemotherapy-induced toxicity [51].
Both ghrelin and ghrelin analogues are currently being tested
in clinical trials. Among these, anamorelin was recently
shown to improve lean body mass, total body mass, and hand
grip strength in patients affected by NSCLC [52]. Other stud-
ies, however, showed that anamorelin administration to can-
cer patients increased body weight and improved FAACT
scores while did not enhance hand grip strength [53].
2.3. Amino Acids. In addition to be necessary to synthesize
proteins, free amino acids (FAA) also act as regulators of pro-
tein metabolism. In particular, plasma FAA, that even repre-
sent a small fraction of the total amino acid pool, are the
main source of metabolically active nitrogen compounds.
Among FAA, the essential amino acids were reported to
stimulate protein synthesis and to inhibit protein degrada-
tion. Such a role is mainly played by the three branched chain
amino acids (BCAA), leucine in particular.
Alterations of amino acid metabolism are frequent fea-
tures in cancer-induced muscle wasting. Reduced amino acid
uptake was generally observed in cancer patients, mainly due
to the occurrence of anorexia, which also leads to decreased
insulin secretion. Both decreased amino acid availability
and insulin levels inhibit the anabolic pathway dependent
on mTOR, resulting in downregulation of protein synthesis
rates and stimulating protein degradation. Inhibition of
mTOR signaling in cancer cachexia is enforced by proinflam-
matory cytokines [1]. Reduced amino acid uptake in the
muscle was also reported to derive from altered amino acid
transport. Indeed, in the soleus muscle of tumor-bearing rats,
the activity of system Awas decreased, while no changes were
observed for systems L and ASC [54]. Of interest, TNFα was
shown to impair amino acid transport in tumor-bearing rats
[55]. Plasma glutamine levels were shown to be significantly
reduced in tumor-bearing rats with respect to healthy ani-
mals [56]. Of interest, reduced glutamine availability could
activate the metabolic sensor adenosine monophosphate-
activated protein kinase (AMPK, see below; [57]). Finally,
leucine oxidation was markedly increased in the muscle of
rats bearing the Yoshida AH-130 hepatoma [58]. Consis-
tently, enhanced activity of the BCAA dehydrogenase was
reported in rats bearing the Walker 256 carcinoma [59].
Several studies have proposed amino acid supplementa-
tion as a mean to improve cancer-induced muscle wasting.
In experimental models of cancer cachexia, BCAA were
shown to attenuate the loss of muscle mass. The underlying
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mechanisms of such effect are not clear, although downregu-
lation of protein degradation and stimulation of protein syn-
thesis were hypothesized [60]. More recently, metabolomic
alterations were proposed to be the basis of the positive
effects exerted by a leucine-rich diet on cachexia in rats bear-
ing the Walker 256 carcinoma, in the absence of effects on
tumor mass [61]. As for clinical studies, BCAA were pro-
posed to improve anorexia [62], thus removing, partially at
least, one of the mechanisms accounting for reduced amino
acid uptake. Other studies supported a beneficial role of
BCAAs on muscle protein metabolism, although this should
be confirmed by larger randomized, blind, placebo-
controlled trials [63].
Beta-hydroxy-beta-methylbutyrate (HMB), a metabolite
of leucine, was shown to improve muscle wasting in experi-
mental cancer cachexia, mainly by inhibiting protein degra-
dation rather than stimulating protein synthesis [63].
Recently, HMB was proposed to be more effective than
leucine in preventing body weight loss in tumor-bearing ani-
mals [64]. Such effect, however, could depend on the model
system chosen, since HMB does not appear able to modulate
muscle mass in mice bearing the C26 tumor (Costelli et al.,
unpublished observations). The situation is even more con-
fused in human cachexia. Increase of both hemoglobin levels
and fat-free mass were reported in advanced cancer patients
administered a nutritional supplement containing HMB,
arginine, and glutamine [65, 66]. Another study, however,
was not able to demonstrate a beneficial effect of the same
supplement in cancer patients [67], suggesting that the effec-
tiveness of HMB in the clinical practice is still unclear and
deserves further investigation.
Glutamine supplementation was reported to attenuate
muscle protein wasting in cancer patients [68], as well as to
improve the energy balance in rats bearing the Walker 256
tumor [69]. Finally, promising data are available about the
possibility to treat cancer hosts with L-carnitine, an amino
acid derivative that plays a role in fatty acid metabolism
and energy production [63].
3. Energy Metabolism
A negative energy balance, generally resulting from both
reduced production and increased expenditure, is a frequent
occurrence in cancer patients. While resting energy expendi-
ture (REE) frequently increases, likely due to enhanced ther-
mogenesis, the occurrence of reduced physical activity,
particularly in advanced cancer patients, paradoxically leads
to a net decrease of total energy expenditure. The increased
thermogenesis is consistent with the observation that in
cachectic tumor-bearing animals, the expression of the
brown adipose tissue- (BAT-) specific uncoupling protein 1
(UCP1) is higher than in controls, while UCP2 (ubiquitous)
and UCP3 (expressed in BAT and muscle) levels increase in
the skeletal muscle only [70]. Similarly, muscle UCP3 mRNA
levels were higher in weight-losing than in non-weight-losing
cancer patients or controls [71].
The increase of REE in cancer cachexia is not a new
observation; however, just recently, the underlying mecha-
nisms start to be clarified. A central point in this regard is
played by muscle mitochondria compartment, which is
markedly affected in tumor hosts. Indeed, both morphologi-
cal [72, 73] and functional alterations [74, 75] were reported
in experimental tumor-bearing animals. In particular, mito-
chondrial uncoupling and reduced oxidative capacity were
associated with myofiber shift from oxidative to glycolytic
fibers [73]. Impairment of the mitochondrial compartment
results in decreased ATP production, leading to an energy
deficit that becomes even worse since it is coupled with
steadily increased REE. Consistently, reduced ATP levels
and increased activity of the energy sensor AMPK were
shown in the muscle of tumor-bearing animals [72, 73].
The lack of an appropriate energy supply results in compro-
mised cell function and reduced contractile force generation,
leading to loss of muscle mass and strength.
Several factors can lead to mitochondrial alterations in
the skeletal muscle. Among these, proinflammatory cyto-
kines play a major role. Indeed, the activation of NF-κB
induced by TNFα was reported to reduce both muscle oxida-
tive capacity and the expression of factors regulating mito-
chondrial biogenesis. Similar observations were reported
when other inflammation-driven pathways such as the IL-
6/STAT3 or TGFβ/Smad3 are activated above physiological
levels [76]. In addition to proinflammatory mediators, also
oxidative stress, due to reactive oxygen and nitrogen species
levels exceeding the compensative capacity of the intracellu-
lar antioxidant systems, contributes to mitochondrial func-
tion impairment. In this regard, there are several studies
sustaining the involvement of oxidative stress in cancer-
induced muscle wasting, although a clear-cut causative
evidence is still lacking [77] (Ballarò et al., unpublished data;
Figure 2).
Being mitochondria crucial to the maintenance of muscle
oxidative metabolism, emergency routes can be activated in
order to avoid mitochondrial dysfunction. In particular,
mitochondrial biogenesis and dynamics as well as the
disposal of damaged organelles, mainly by mitophagy, are
promoted (Figure 2). The other way round, impaired func-
tion of the emergency routes themselves could trigger the
accumulation of altered mitochondria resulting in reduced
muscle oxidative metabolism. In this regard, the expres-
sion of the peroxisome proliferator-activated receptor-γ
(PPAR-γ) coactivator-1α (PGC-1α), the master regulator
of mitochondrial biogenesis and oxidative metabolism, was
shown to be reduced in the skeletal muscle of tumor-
bearing mice [78], although this is not a constant finding
[73, 79]. Mitochondria dynamics, representing the balance
between fission and fusion processes, was shown to be altered
in both experimental cancer cachexia and in cancer patients
[78, 80]. In this regard, impaired mitochondrial dynamics
could drive the hyperactivation of muscle protein break-
down, likely through pathways depending on AMPK and
FoxO, eventually leading to muscle wasting [81, 82].
Autophagy (mitophagy) is the main mechanism respon-
sible for disposal of altered mitochondria. Also, mitophagy
was reported to be impaired in cancer cachexia, as shown
by the observation that Bnip3L and Parkin1 mRNA
increased in the muscle of cancer patients [17]. Similarly,
Bnip3L protein levels were increased in the muscle of mice
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bearing the Lewis lung carcinoma [73]. On the whole,
these observations suggest that in addition to mitochon-
dria biogenesis and dynamics, also their disposal is
perturbed in the skeletal muscle of tumor hosts, thus con-
tributing to mitochondrial dysfunction and reduced mus-
cle oxidative metabolism.
Several strategies were proposed to improve energy
metabolism by acting onmitochondria. The first and perhaps
simplest one, in theory at least, is exercise training, in partic-
ular a combination of both resistance and endurance exer-
cise. These two types of training affect different but
complementary targets, being able to improve force produc-
tion and metabolic adaptations, respectively. Of particular
relevance is the observation that endurance training was
reported to increase the number of mitochondria and to
drive myofiber-type shift from glycolytic to oxidative, thus
specifically targeting alterations that characteristically occur
in the skeletal muscle of tumor hosts. However, these poten-
tially favorable effects can be exploited just systematically
practicing exercise, even if at a moderate level. This may
not be an easy task in cancer patients that frequently present
with chronic fatigue and comorbidities eventually leading to
exercise intolerance. This point is supported by the observa-
tion that C26-bearing mice did not benefit from exercise
training, suggesting that the effort to exercise in already com-
promised animals was damaging rather than protective [73].
Consistently, excessive endurance exercise was associated
with increased mitochondrial fission in the absence of mito-
phagy induction [83].
In the last years, the possibility to mimic the effects of
exercise by drugs has been gaining a growing consensus.
The positive side is that this strategy will allow to overcome
both poor patient compliance to exercise training and possi-
ble occurrence of exercise intolerance. The negative part is
that generally exercise mimicking drugs do not totally reca-
pitulate the effects of exercise itself. In this sense, these drugs
do not properly hit the target; however, they could be a good
compromise when exercise training cannot be proposed to
the patient.
At present, several options were investigated as exercise-
mimicking strategies. While most of them are pharmacolog-
ical, also a genetic approach was proposed. This latter
consists in manipulations able to increase the levels of
PGC-1α in the skeletal muscle. In this regard, improved exer-
cise capacity and oxidative metabolism were reported in mice
specifically overexpressing this factor in the muscle, resem-
bling the phenotype induced by endurance training [84].
PGC-1α overexpression was shown to interfere with muscle
atrophy induced by activation of the TWEAK-Fn14 pathway
[85] and to improve cancer-induced muscle wasting in
tumor-bearing mice [73, 86], although contrasting data were
previously reported [87].
Several classes of drugs were proposed to modulate
energy metabolism, among which are activators of AMPK,
sirtuin 1 (SIRT1), and trimetazidine (TMZ).
Different compounds such as resveratrol, metformin,
quercetin, and AICAR can activate AMPK [88]. In this
regard, AICAR administration was shown to impinge on
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Figure 2: Mechanisms by which inflammation can impinge on muscle energy metabolism.
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exercise capacity, oxygen consumption, and fatty acid oxida-
tion [89]. Muscle atrophy induced by angiotensin II was pre-
vented by treatment with AICAR. This drug also revealed
able to activate autophagy and to improve muscle phenotype
in both dystrophic mdx mice and animals bearing the C26
tumor [16, 90]. Metformin administration was shown to
improve sarcopenia of aging and muscle wasting in severely
burned patients [91, 92] and was proposed to be useful to
treat muscle wasting in cancer cachexia [93]. AMPK activa-
tion can also be induced by resveratrol, as demonstrated by
the observation that AMPKα1- or AMPKα2-deficient mice
were refractory to resveratrol-induced increase of both
mitochondrial biogenesis and endurance exercise capacity
[94]. Consistently, obese men receiving resveratrol showed
improved inflammation, AMPK activation, and increased
expression of PGC-1α and SIRT1 protein levels [95]. Finally,
an AMPK-stabilizing peptide was reported to improve white
adipose tissue wasting in tumor hosts [96].
SIRT1 belongs to a class of deacetylases deregulated in
aging and in different chronic diseases, including cancer.
SIRT1 is also involved in the regulation of energy homeosta-
sis; its expression is induced in response to caloric restriction
[97] and can be activated in the skeletal muscle by AMPK
[98]. Specific overexpression of SIRT1 in the muscle resulted
in a fast-to-slow myofiber type transition, producing an
oxidative phenotype. Consistently, muscle-specific SIRT1
transgenic mice exposed to fasting or denervation showed a
reduced expression of atrogenes in comparison with wild-
type littermates [99]. Finally, improved muscle phenotype
was reported in mdx/SIRT1 double transgenic mice [100].
In addition to AMPK, resveratrol also activates SIRT1. In this
regard, part of the above-described effects exerted by resver-
atrol derive from SIRT1-dependent modulations of PGC-1α
acetylation state [101]. Synthetic selective SIRT1 activators
such as SRT2104 are also available [102, 103]. Plasma lipid
profile and insulin sensitivity were improved in healthy
volunteers by administration of SRT2104 [102, 104]. Very
few studies are actually available about SRT2104 action on
both muscle mass and function. In this regard, SRT2104
appeared to reduce the depletion of muscle mass due to
fasting or inactivity [105], at least in part by increasing
PGC-1α expression [105].
TMZ is a metabolic modulator that blocks fatty acid
oxidation, shifting ATP production to glucose oxidation
and improving cell energy metabolism. Indeed, ATP synthe-
sis through fatty acid β-oxidation requires more oxygen than
glucose oxidation [106]. Along this line, the shift to glucose
oxidation improves the use of the available oxygen, possibly
increasing metabolic efficiency and skeletal muscle function.
TMZ was shown to increase the size of cultured myotubes
[107] and to improve both heart metabolism and exercise
capacity in patients suffering from chronic stable angina
[108]. When administered to aged animals, TMZ resulted
in increased muscle strength [109]. Finally, treatment of
C26-bearing mice with TMZ resembled some of the benefits
triggered by exercise, among which fast-to-slow myofiber
phenotype shift, PGC-1α upregulation, oxidative metabolism
enhancement, and grip strength increase (Molinari et al.,
unpublished). The relevance of fatty acid oxidation to
cachexia is also supported by a recent study showing that sev-
eral tumor cell lines are able to release proinflammatory
mediators, resulting in enhanced fatty acid oxidation and
activation of p38-dependent signaling in the skeletal muscle,
well before tissue wasting occurs. In addition, the same study
also showed that treatment of tumor-bearing animals with
etomoxir, an inhibitor of fatty acid oxidation, rescued both
muscle mass and body weight [110].
4. Concluding Remarks
A complex network of metabolic alterations sustained by
hypercatabolism, energy deficit, and systemic inflammation
is the milieu underlying cancer cachexia. While becoming
overtly detectable in advanced cancer patients, such pertur-
bations likely take place very early in the course of the
disease, at least at the molecular level.
Protein and energy dysmetabolism in cachexia are quite
well recognized; however, the available therapeutic strategies,
although frequently promising from the preclinical point of
view, have not yet reached validation to be used in the clinical
practice. Several drugs identified by experimental studies are
currently tested in clinical trials for their ability to improve
muscle metabolism in cancer patients. Other emerging
strategies are those aimed at interfering with the intestinal
microbiota, previously reported to improve cachexia in a pre-
clinical model [111].
The available results of both experimental and clinical
studies, however, have clearly indicated that single-targeted
therapies will hardly be successful in the treatment of
cachexia. In this regard, the view of a multidirectional
approach, selectively tailored and, whenever possible, per-
sonalized, is gaining a growing consensus. Such an approach
should not just rely on nutritional counseling and pharmaco-
logic treatment with anti-inflammatory and anticatabolic
drugs but also include exercise training and/or exercise-
mimicking agents. In this regard, exercise mimetics could
not only merely replace exercise training in depleted patients
but also improve exercise tolerance and effectiveness in pre-
cachectic individuals, thus amplifying the beneficial action
of exercise itself. Last but not least, treatments aimed at pre-
venting/correcting the metabolic alterations underlying
cancer-induced muscle wasting might also impinge on
tumor-targeted therapies improving their effectiveness and/
or enhancing patient tolerance to chemotherapy. In addition,
metabolic modulators could also directly affect tumor
growth. This is the case, for example, of exercise, that was
shown to prevent or at least delay tumor growth [112].
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